Purpose: Manganese ion has been extensively used as a magnetic resonance imaging (MRI) contrast agent in preclinical studies to assess tissue anatomy, function, and neuronal connectivity. Unfortunately, its use in human studies has been limited by cellular toxicity and the need to use a very low dose. The much higher sensitivity of positron emission tomography (PET) over MRI enables the use of lower concentrations of manganese, potentially expanding the methodology to humans. Procedures: PET tracers manganese-51 (Mn-51, t 1/2 = 46 min) and manganese-52 (Mn-52, t 1/2 = 5.6 days) were used in this study. The biodistribution of manganese in animals in the brain and other tissues was studied as well as the uptake in the pancreas after glucose stimulation as a functional assay. Finally, neuronal connectivity in the olfactory pathway following nasal administration of the divalent radioactive can be used to trace neuronal connections analogous to manganese-enhanced MRI neuronal tracing studies.
Introduction
Manganese-enhanced magnetic resonance imaging (MEMRI) has been used in animals to image different organs including liver, kidney, pancreas, spleen, heart, and brain. There have been three major uses of MEMRI. One use is to study tissue anatomy including liver, kidneys, heart, and pancreas following systemic administration of manganese [1] [2] [3] [4] , as well as to image anatomy and cytoarchitecture of the brain where layers in the cortex, olfactory bulb (OB), hippocampus, and cerebellum can be detected [5, 6] . A second use of MEMRI is to monitor cellular activity due to the ability of Mn 2+ to enter excitable cells through voltagegated calcium channels in the brain, heart, and pancreas [1, [7] [8] [9] . Increased activity in these tissues leads to an increased Mn 2+ influx through calcium channels, which results in an increased signal intensity in magnetic resonance imaging (MRI). MEMRI has been used to study regional brain activity following somatosensory stimulation [7] and changes in cardiac inotropy [8] . Glucose load prior to manganese infusion increases pancreatic manganese ion uptake, which depends on the number of functioning β-cells [1] . A third use of MEMRI is to enable neuronal tract tracing following administration of Mn 2+ into specific regions in the brain. This is due to the ability of Mn 2+ to be transported along axons in an anterograde manner and to cross synapses to trace neuronal pathways [10] . After intranasal or intraocular manganese administration in rodents and monkeys, manganese traces olfactory and visual pathways, respectively, over a course of several days [10] [11] [12] [13] [14] . Other MEMRI tract tracing studies used direct injection of manganese into specific brain areas to study the song control pathway in songbirds [15] , somatosensory neuronal connections in rats [16, 17] , and neuronal connections of the basal ganglia in rats and monkeys [14, 18, 19] .
The major limitation of manganese as an MRI contrast agent in humans is its cellular toxicity and therefore the need to use as low a dose as possible. Several clinical studies have used the FDA-approved agent mangafodipir (MnDPDP, Teslascan), a chelated Mn 2+ contrast agent, to image healthy volunteers and patients with liver metastases, pancreatic cancer, and myocardial infarction [20] [21] [22] . This agent dissociates rapidly in the blood with most of the contrast that is detected interpreted as representing the released Mn 2+ . The FDA-approved label indication for detection of liver metastases did not warrant further production of this contrast agent and therefore it is no longer widely available. Furthermore, FDA-approved doses are too low for many applications.
Radioactive manganese tracers have previously been used in physiologic studies, raising the possibility of obtaining information typically derived from MEMRI by using positron emission tomography (PET) in lieu of MRI. Manganese-54, a gamma-emitter (Mn-54, t 1/2 = 312.5 days), has been used to study the accumulation and retention of manganese, after dissection, of body tissues in mice and monkeys [23, 24] and to trace its distribution in specific neuronal connections in the brain of rats [25] [26] [27] . In the late 1960s, Mn-54 was given intravenously to healthy human volunteers to study its whole body retention [28, 29] , with limited clinical use due to its long half-life and high gamma energy. Manganese-52m (Mn-52m, t 1/2 = 21.1 min) was suggested as a potential PET tracer for myocardial imaging [30, 31] and was shown to detect infarction in the heart of dogs [30] .
In recent years, there has been a renewed interest in using radioactive manganese for PET imaging, in particular Mn-52 [32] [33] [34] [35] [36] [37] . Mn-52 is a positron emitter with a long half-life of 5.6 days, which allows longitudinal biodistribution studies in the body and brain. In the present study, Mn-51 and Mn-52, positron-emitters with a physical half-life of 46.2 min and 5.6 days, respectively, were used in both rats and macaque monkeys. The results show that manganese radiotracers give similar information as Mn 2+ in MRI with accumulation in various tissues following systemic infusion even at low concentrations. Mn-51 PET was also used to follow activityinduced manganese accumulation in the pancreas during a glucose load. Finally, Mn-52 PET was used to trace olfactory pathways in the brain following intranasal administration in monkeys. These results add to the accumulating evidence that there will be a wide variety of potential applications for the use of manganese-based radiotracers in both preclinical and clinical studies to assess anatomical, functional, and neuronal connectivity information by PET.
Materials and Methods
All animal studies were approved by the Animal Care and Use Committees of the National Institute of Neurological Disorders and Stroke (rats), and the NIH Clinical Center (monkeys) and were performed in accordance with the regulations of the Division of Radiation Safety, at the National Institutes of Health (Bethesda, MD, USA).
Radiotracer Production
Radionuclides of Mn-51 and Mn-52 were produced on a CS30 cyclotron at the NIH Cyclotron Facility and assayed on a Capintec 127 Dose Calibrator utilizing a pot setting of 551 for Mn-51 and 710/2 for Mn-52. Radionuclidic purity was determined by spectral analysis on a Princeton GammaTech HPGeLi detector.
To produce Mn-51, electroplated Cr-50 metal (3-5 mg, 9 99 % isotopic purity) on solid gold internal target plates were irradiated with 60-80 μA of a 14-MeV deuteron beam for 50 min. Manganese-51 was isolated using a modified method of Klein and co-workers [38] . Briefly, irradiated chromium target was taken up in hot 6 N HCl. The mixture was oxidized by the addition of 10 M NaOH and 10 M H 2 For Mn-52, pressed pellets of vanadium metal (200 mg; Alfa-Aesar, 9 99.86 % isotopic purity with residual as listed on Certificate of Analysis: Fe (0.04 %), Al (0.0012 %), C (0.04 %), O (0.04 %), Si (0.01 %), Cr (0.03 %), N (0.035 %), and H (0.0008 %), and no carrier manganese metal in the target material) in an aluminum target cup were irradiated with 15-20 μA of a 19 MeV He-3 beam for 28-36 h over a 4-day period. No long-lived Mn-54 was detected at EOB. Manganese-52 was isolated using a modified method of Sastri et al. [39] . The irradiated vanadium metal was removed from the target cup and taken up in hot HNO 3 . The radioisotope mixture was treated with saturated KIO 3 , heated to boiling, and allowed to cool. [
52 Mn]Mn(II) was extracted as the oxinate with a 0.1 M chloroform solution of 8-hydroxyquinoline. The extracted chloroformhydroquinone solution containing only Mn-52 was reduced to dryness under vacuum, and excess hydroquinone was removed by sublimation. The dried organic layer was backextracted with a mixture of 0.1 N HCl and 10 % v/v ethanol. The pH was adjusted and the Mn-52 solution diluted and buffered with 1 M bicine. The solution was tested for carrier manganese, and pH was recorded. The yield was 11-41 MBq (0.3-1.1 mCi) Mn-52/ml.
Rat Whole Body MEMRI and Mn-51 Imaging Procedure
Male Sprague-Dawley rats (250-350 g, n = 10) were used in this study. For Mn-51 administration, rats were anesthetized with isoflurane and a 22G IV catheter was inserted into the tail vein for tracer administration. Rats were then injected intraperitoneally (IP) with Inactin (Sigma-Aldrich), 100 mg/ kg bodyweight in water and isoflurane was discontinued. Inactin maintains rats under stable anesthesia for 3-4 h, the duration of the PET imaging session. After assuring anesthesia was maintained, rats were positioned in the scanner and Mn-51 radiotracer, 15-33 MBq (0.4-0.9 mCi) in 1 ml was infused using a syringe pump at a rate of 5 ml/h (infusion time~12 min). Mn 2+ concentration in the infused solution was lower than 0.05 mM, which reflects the situation where a manganese test strip would give positive results of G 1 ppm for the presence of bulk manganese in the radiotracer solution. Although no production runs of Mn-51 (and Mn-52) solutions gave a positive test for the presence of Mn 2+ , we later use this concentration, 0.05 mM, for comparison with Mn 2+ concentrations used in MRI. PET imaging started with the beginning of radiotracer administration to follow the course of the radiotracer in the body for 2.5 h. After imaging, while still under anesthesia, animals were euthanized with an overdose bolus of potassium chloride (KCl, 10 mg/ml), 2.0 ml/rat, via the tail vein line.
For MEMRI body imaging, rats were anesthetized with isoflurane and 25 mM MnCl 2 (Sigma-Aldrich) solution, on the lower end of the concentration range typically used for systemic infusion in MEMRI, was infused through a tail vein catheter using a syringe pump (Cole-Parmer Instrument) at a rate of 5 ml/h, total volume 1 ml (infusion time~12 min). After a baseline pre-Mn 2+ scan, MEMRI imaging started with the beginning of manganese administration similar to the PET procedure for 2.5 h. During imaging rats were anesthetized with 1-2 % isoflurane.
Rat Mn-52 Brain and Whole Body Imaging Procedure
Mn-52 solution, 4-7 MBq (0.1-0.2 mCi), in 2 ml was infused through a tail vein catheter using a syringe pump at a rate of 5 ml/h. Twenty-four and 48 h after infusion, rats were given an IP injection of Inactin (100 mg/kg bodyweight in water) as previously described. After assuring anesthesia was maintained, rats were positioned in the scanner and imaged for 1 h. After imaging, while still under anesthesia, rats were euthanized with a lethal dose of KCl as described above.
Monkey Mn-51 Whole Body and Pancreas Imaging Procedure
Five rhesus macaque monkeys were included in this study (9-15 years of age, weight 7-14 kg). Each underwent one to two whole-body imaging sessions during the course of this study, with at least 6 months between imaging, for a total of eight sessions. In each session, Mn-51 was infused intravenously at a dose of~333 MBq (~9 mCi) in 12 ml over 5 min using a Harvard® pump. Two sessions were excluded from the study because the infused radiotracer dose was only 74-111 MBq (2-3 mCi). Monkeys were anesthetized with ketamine IM for IV insertion and endotracheal intubation and then transported to the PET suite. They were placed in a stereotactic head holder in the prone position in the PET/CT scanner, and anesthesia was maintained with isoflurane. PET imaging started with the beginning of radiotracer administration for a total of 2 h. Before and during scanning, the vital signs, e.g., heart rate, respiration rate, and body temperature, were measured continuously to check for any effects due to tracer administration. In three sessions, arterial blood samples were taken before, during, and after Mn-51 infusion, through an indwelling arterial port that was placed several months earlier. Samples of 0.5 ml were drawn every 15 to 60 s in the first 10 min and every 2 to 10 min after that until the end of scanning, and counted on a Packard COBRA® gamma counter to follow manganese clearance from the blood.
To determine if there was activity-induced manganese enhancement in the pancreas, a 50 % dextrose (Hospira) solution, 0.3 g/kg bodyweight, was administered IV over 2 min prior to infusion of the radiotracer. Vital signs and blood glucose levels were taken before and after glucose injection and after Mn-51 infusion, to check for any physiologic effects of glucose or tracer administration.
Monkey Mn-52 Nasal Administration Imaging Procedure
In this study, four monkeys were used. Each monkey was anesthetized with ketamine 10 mg/kg, acepromazine 0.2 mg/ kg, and glycopyrrolate 0.01 mg/kg or atropine 0.05 mg/kg (all IM), and was positioned supine with the head extended back to facilitate administration of the divalent radioactive Mn-52 ([ 52 Mn]Mn 2+ ) into the nose. A total of 7-22 MBq (0.2-0.6 mCi) of [
52 Mn]Mn 2+ were administrated into both nostrils using a plastic pipette, 0.5 ml into each nostril. After radiotracer administration, each animal was either transported to the PET/CT for scanning or moved back to housing. To follow [
52 Mn]Mn 2+ distribution in the brain at different time points, the animal had three scan sessions, from immediately after to up to 1 week after Mn-52 administration, with at least 1 day between scans. The head was scanned for 1 h followed by a whole-body scan to study radiotracer distribution in the rest of the body.
PET and MRI Imaging Procedure
PET imaging was performed on either a Siemens High Resolution Research Tomography (HRRT) scanner,2
.5 mm resolution (rats) or on a Siemens mCT® PET/CT scanner,~3.5 mm resolution (monkeys). Due to the substantial positron range of Mn-51 of 4.3 mm, the effective resolution for Mn-51 studies was 5.5 mm, unlike F-18 and Mn-52, both with positron range of 0.6 mm and resolution of 3.5 mm. For dynamic whole-body PET imaging (Mn-51), scanning started with injection of radiotracer and continued for up to 2.5 h. For static whole body (rats) and brain (monkeys) scanning, Mn-52 images were acquired for 1 h. This is in accord with the relatively long half-life of the radiotracer (5.6 days), as well as with its relatively stable biodistribution due to the slow in vivo transport rate of manganese estimated as 2 mm/h in rodent's brain [10] . For monkeys, a 1-h brain scan was followed by a 20 min wholebody scan. For the HRRT scanner, a transmission scan was obtained with a point source of Cs-137 for attenuation correction, while for the PET/CT scanner, a CT scan was performed for attenuation correction and anatomical image localization. Reconstruction of the PET images was performed using the OSEM (ordered subset expectation maximization) iterative reconstruction method; a correction for additional gamma decays was applied during Mn-52 image reconstruction. Rat whole-body MRI images were acquired on a 4.7-T Bruker Avance III scanner with a 72-mm ID birdcage coil. Body MEMRI images were acquired using a T 1 -weighted fast low-angle shot (FLASH) sequence with 2-mm slice thickness, 400 μm in plane resolution, TR/TE = 200/2.7 ms, 60 o pulse, bandwidth = 100 kHz, FOV = 9 × 8 cm 2 , matrix size = 225 × 200, number of averages = 4; each scan was3 min long. Scanning was done for 2.5 h.
A summary of all imaging procedures is presented in Table S1 .
Data Analysis
Data processing was done using Medical Image Processing, Analysis, and Visualization (MIPAV) software (NIH; http:// mipav.cit.nih.gov). PET measurements were done by manually defining the ROI for each organ. For monkeys, CT scans were used to help with ROI placement. Activity measurements were obtained for each organ over time for each animal and were used to create decay-corrected time activity curves (TAC) and standardized uptake value (SUV) curves. For pancreas analysis, the pancreas for each monkey was identified by two independent radiologists using only the CT scan; ROIs were drawn on the CT images and then applied to the PET images for activity measurements, and pancreas ROIs from all monkeys were averaged together.
MRI measurements were performed in a similar way using MIPAV. ROIs were manually drawn, and intensity was measured for the heart, liver, and kidneys over time. ROIs were also drawn in the muscle area, where no manganese was found to accumulate following manganese administration. Muscle ROIs were drawn at each time point on the same slices in which the organs ROIs were drawn and were used for normalization of the signal intensity.
For studies using nasal administration of tracer, PET images were co-registered to MRI images of the same monkey (3D T 1 -weighted brain MRI, acquired on a 3-T Philips Achieva scanner, with 1-mm slice thickness, TR/ TE = 25/4.3 ms, 35°pulse, FOV = 100 × 100 mm 2 , number of averages = 2). ROIs of the different compartments of the olfactory pathway were drawn on the MRI images with the help of a monkey atlas [39] and then applied to the PET images. One percent of the maximum intensity in the PET image, which was about 20-30 times above noise level, was used as threshold for tracing in these ROIs. [3, 4] . The kidney and liver manganese accumulation were similar for MRI (Fig. 1d) , but there was lower relative accumulation in the liver for MRI (Fig. 1e) ; this is likely due to the higher amount of Mn 2+ used in MRI. The specific cause of this alteration of liver uptake could either be due to saturation of Mn 2+ uptake in the liver at MRI doses, or limitations to detect further changes in T 1 due to imaging parameters used in this study. This warrants further investigation.
Results

Mn
The relatively low resolution of PET together with the small size of the rat limits our ability to study tracer (Fig. 2b) . This is in agreement with previous reports showing that Mn 2+ is cleared from the blood very rapidly over a course of minutes after administration [2, 24] . In the data shown in Fig. 2b, activity in the left ventricle increases in the first few minutes and decreases quickly, due to rapid clearance of manganese from the blood pool (Fig. 2e) , which is similar to the blood activity curve in Fig. 2b , respectively, and the corresponding time intensity curve from d MRI and e standardized uptake value (SUV) curve from PET. Values are average ± standard deviation (SD), MRI n = 4, PET n = 6. The highest manganese accumulation was in the liver and kidneys followed by the heart. For both MRI and PET, manganese was infused through the tail vein for 12 min. those previously reported in MRI studies with systemic administration of manganese.
Glucose Increases Mn-51 Activity in the Pancreas
The pancreas has been the focus of many studies relevant to diabetes mellitus for estimating β-cell mass and function. In MRI studies, stimulation with glucose prior to manganese infusion results in increased accumulation of Mn 2+ in the pancreas or in isolated β-cell islets that can be detected with MRI [1, 40, 41] 3 g/kg) . For each monkey, the pancreas was identified by two independent radiologists using the CT scan. An ROI was drawn on the CT image and applied to the PET image for radioactivity measurements. 51 Mn]Mn 2+ , and any difference was not statistically significant in the liver, kidneys, and heart in both cases. To further test if the increased manganese was glucose-specific to the pancreas, the ratio of manganese accumulation in the pancreas to that in the kidneys was calculated (Fig. 3f) . The average ratio was6 0 % higher for monkeys that received glucose stimulation. Therefore, glucose increased [
51 Mn]Mn 2+ uptake in the pancreas.
Whole-Body Imaging with Mn-52
Systemic administration of manganese results in excellent contrast in the brain 24 h later in MRI studies [5] . Due to its 2+ infusion in monkeys (n = 3); values are average ± one standard deviation (SD). c PET/CT images over time in the heart, liver, and kidneys of a monkey following IV infusion of [ 51 Mn]Mn 2+ ; d the corresponding standardized uptake value (SUV) curve (average and SD, n = 3) and e SUV curve for the heart (average and SD, n = 3). Highest activity was detected in the liver and kidneys, and then heart, similar to rats. LV left ventricle, LVW left ventricular wall.
short half-life of 46.2 min, Mn-51 cannot be used to study manganese accumulation in different brain areas 24 h post IV administration. The half-life of Mn-52 (5.6 days) allows for imaging at longer time points following tracer infusion as seen in Fig. 4a Fig. 1a ) including the brain, via the choroid plexus and the cerebrospinal fluid, similar to MEMRI results in the rodent brain [5, 6] . The head area of the MIP image is shown in Fig. 4b and is compared to an MRI image projection of a rat head following Mn 2+ administration, Fig. 4c . Although PET image resolution is lower than that of MRI, 2.5 mm compared to 400 μm, respectively, the radiotracer can be identified in different areas in the brain and head, such as the nasal turbinates, OB, hippocampus, pituitary gland, and salivary glands. Figure 4d , e shows the PET and MRI images at different slices across the head, where manganese accumulated in various areas. Thus, the long half-life [ 52 Mn]Mn 2+ allowed a visualization of relative distribution in the head and brain similar to that detected with MEMRI.
Mn-52 Neuronal Tract Tracing
MEMRI has been used to track neuronal connections in the brain when administrated into specific brain areas in animals, in particular, into the nostril from which it can trace the olfactory pathway as far as the amygdala over several days [12] . [
52 Mn]Mn 2+ was administered into the nostril of four monkeys at day 0, and PET images were obtained on different days and then co-registered with the corresponding MRI images. PET images on day 0 and day 7 for coronal slices going from the nose and through the brain following nasal administration of [ 52 Mn]Mn 2+ are shown in Fig. 5a , b. At day 0, the radiotracer is localized only in the nose. By day 7, the [ 52 Mn]Mn 2+ has traced into the brain, from the nose to the amygdala. The radiotracer follows the olfactory pathway, as can be seen in Fig. 5c with the comparison to the corresponding atlas slices [42] . The [ 52 Mn]Mn 2+ is traced to the olfactory bulb, the olfactory tract, olfactory nucleus, piriform cortex, the amygdala, and frontal cortex. This is in accordance with the olfactory pathway in the Old World monkey previously described using electrophysiological studies [43] (see Fig. 49 in [43] ).
At the same PET scanning session, whole-body PET imaging was also performed on each monkey to follow radiotracer distribution in the rest of the body, as shown in Fig. S2 . Immediately after [
52 Mn]Mn 2+ administration, the radiotracer is localized in the nose area; however, some of the tracer was also swallowed and progressed along the esophagus to the stomach. One day later, the majority of the swallowed manganese is cleared from the body via the digestive system and bladder with a small amount of manganese detectable in the liver and kidneys. Manganese continues to be cleared from the body through the digestive system and, by day 7, only a small amount can be detected in the liver and kidneys. Figure 6a shows the temporal progress of the radiotracer into the brain starting immediately after [ , and f the pancreas to kidney ratio curve. ROIs were selected using the anatomy from the CT scan and then applied to the PET image.
administration into the nostril until 7 days later, across all the monkeys studied. Immediately following administration, the tracer is visualized only in the nose. By day 1, it is seen in the OB, olfactory tract, and olfactory nucleus. By day 3, it can be detected in the piriform cortex, and by day 4, it has reached the amygdala. The intensity of tracer accumulation further increases in the piriform cortex and amygdala at days 6 and 7, when tracer is also detected in the frontal cortex. A summary of the results from the four studies is shown in Fig.  6b , where each study is represented by a different color. Over time, the [ 52 Mn]Mn 2+ moves deeper through the olfactory pathway.
Discussion
This study demonstrates that manganese-based PET radiotracers behave in a manner similar to that of manganese when used as a contrast agent in MRI. This is true despite the 2000-fold lower concentration used (~100 [10, 12, 13] .
In this work, IV infusion of [ 51 Mn]Mn 2+ in both rats and monkeys shows high accumulation of the radiotracer in numerous body tissues, with the highest radioactivity in the liver, kidneys, and then in the heart, with very little accumulation in the brain. These results are consistent with previous MRI studies in rodents [3, 4] . Systemic administration of Mn-54 (t 1/2 = 312.5 days) in mice and monkeys was also reported to result in high accumulation of manganese in the kidney, liver, heart, pancreas, and salivary glands in the days following administration [23, 24] . Interestingly, the pancreas showed the highest level of radiotracer after 24 h in mice and monkeys [24] . [33, 35, 44] . In the heart, the initial high activity in the cardiac chambers reflects blood pool activity. The clearance of manganese from the blood occurs over the course of few minutes [2, 24] which results in the manganese being visualized in the ventricular wall (Fig. 2) .
The high uptake of manganese in the liver and kidneys following systemic administration of [ 51 Mn]Mn 2+ opens the possibility for functional imaging of these organs and study of hepatic and biliary clearance, the main pathway of manganese clearance [45] . Similar to MRI, Mn-PET may be useful for detecting metastases and tumors as cold spots in the liver, since they are not expected to show manganese uptake, and to study renal function and manganese excretion from the kidneys.
The pancreas is an organ that accumulates significant amounts of manganese following systemic administration of Mn 2+ in MRI and in manganese radiotracer studies [4, 23, 24] . β-Cell function has been the focus of many studies due to the importance of this cell type in diabetes. The β-cells in the pancreas are responsible for the synthesis and secretion of insulin in response to the presence of glucose and their destruction or dysfunction is the cause of type 1 and type 2 diabetes. MEMRI studies have shown that infusion of glucose prior to manganese infusion increases manganese uptake in the pancreas and that the amount of manganese uptake depends on the amount of functioning β-cells in the pancreas [1] . Manganese enters β-cells through calcium channels and is taken up by glucose-activated β-cells [40, 41] . Here, we show in NHPs that when [
51 Mn]Mn 2+ infusion followed a glucose infusion, tracer uptake increased in the pancreas. Glucose administration did not affect the accumulation of manganese in other organs, e.g., liver, kidneys, and heart (see Fig. S1 ). This is in agreement with previously reported MRI results [1, 46] 2+ to study the loss of β-cells in the pancreas of animal models of diabetes as well as glucose response, to further explore the applications of Mn-PET for imaging of pancreatic function. The use of Mn-51, with its much shorter half-life compare to that of Mn-52 (46 min vs. 5.6 days), will facilitate rapid repeat scans with lower radiation exposure, especially in humans.
The ability of [ 51 Mn]Mn 2+ to image increased activity of pancreatic β-cells suggests a variety of functional studies in other organs. For example, manganese distribution in the heart was previously used to monitor inotropic states and to study cardiac viability using MRI [2, 8] . As Mn 2+ primarily enters cardiac cells through voltage-gated calcium channels, the rate of influx into the heart can be altered under conditions that increase or decrease myocardial calcium influx. Thus, β-adrenergic agents were shown to increase signal intensity enhancement due to the increased calcium influx. Conversely, calcium channel blockers were shown to decrease the signal intensity enhancement in mice [8] . Moreover, the rapid blood pool clearance of the radiotracer and its long retention in the myocardium make it an attractive candidate tracer for PET myocardial imaging. [ 51 Mn]Mn 2+ may be used to evaluate heart function and viability under different conditions such as ischemia. It should also be possible to infuse [
51 Mn]Mn 2+ during a stress test in one clinical setting and then transfer the patient to the PET for imaging of cardiac distribution. Indeed, Mn-52m (t 1/2 = 21.1 min) was suggested as a potential myocardial imaging agent for PET [30, 31] and was shown to detect infarct areas in the dog heart [30] .
MEMRI studies in rodents have shown that the final distribution of manganese inside the brain following systemic administration is achieved after about 24 h [5, 47] . Therefore, due to its relatively short half-life of 46.2 min, Mn-51 cannot be used to study manganese accumulation in the brain. This was seen in both rat and monkey, where almost no activity was detected in the first 2 h (Figs. 1a and  2a) . However, Mn-52 is suitable for detecting brain structures, due to its 5.6 days half-life, and can be used to image brain anatomy and function and to study pathophysiological conditions. 52 Mn]Mn 2+ administration into the nostrils of monkeys. At day 0, immediately after administration, the radiotracer is localized in the nose area with no activity in the brain. At day 1, it can be seen in the OB, olfactory tract, and olfactory nucleus. By day 3, it was detected in the piriform cortex and by day 4, it traced into the amygdala. The intensity of the tracer increased in the piriform cortex and amygdala at days 6 and 7, when the tracer was also detectable in the frontal cortex. b Summary of the tracing results for the four monkey studies. Each study is represented by a different color and each monkey was scanned on three different days between day 0, immediately after [
52 Mn]Mn 2+ nasal administration, to day 7. ROIs were drawn on the relevant area of the brain and each + sign represents tracing above a threshold of 1 % of the maximum intensity in the image, which was about 20-30 times above noise level. Note that not all monkeys were scanned on each day after day 0.
brain. This included activity in the pituitary gland, which is known to accumulate manganese in the first few hours following Mn 2+ administration, due to its lack of blood-brain barrier (BBB) [5] . Studies with Mn-54 in monkey showed high accumulation of the tracer in pituitary and salivary glands within 2 h after administration, while tissues in the brain retained the Mn-54 for the longest time compare to most other tissues [23] .
[ 52 Mn]Mn 2+ administration into the nostrils of monkeys demonstrates that Mn-PET can be used to trace neuronal pathways in a manner similar to MEMRI. Tjalve et al. [26] used nasal administration of Mn-54 in rats to study the neuronal uptake of manganese through the olfactory pathway over several days. They showed that the olfactory pathway is a route through which manganese can access the brain, by uptake via the olfactory neurons and its migration via secondary and tertiary olfactory pathways into downstream areas. However, the use of Mn-54 required dissecting the brain. Nasal administration of manganese at MRI doses allowed for in vivo imaging of the olfactory pathway [10] . Here, it is shown that nasal [ 52 Mn]Mn 2+ administration in monkeys allows tracing of the olfactory pathway over the course of a few days [10, 12] . After administration, manganese is evident only in the nose area with no uptake in the brain. Subsequent radiotracer accumulation in the brain is the result of tracing of neuronal connections along the olfactory pathway. Four days after administration, the manganese could be traced to the amygdala similar to MEMRI results [12] . Connections to the prefrontal areas could also be detected after a few days. In a recent paper, Mn-52 was used to image the dopaminergic and striatonigral pathways in rats 24 h after tracer injection into the ventral tegmental area and the dorsal striatum, respectively [37] . The ability to follow neuronal connections in the brain following targeted administration of [ 52 Mn]Mn 2+ to a specific area can be expanded to many other neuronal pathways that have been demonstrated with MEMRI, e.g., visual pathway or basal ganglia pathways [10, 11, 14] . was taken into the circulatory system through the nose as well. It would be beneficial to minimize the amount of tracer swallowed either by reducing the volume of tracer solution or by using a better delivery system such as nasal spray used to deliver pharmacological drugs in humans. Most of the swallowed radiotracer was cleared from the monkey's body through the digestive system by 3 days after administration (Fig. S2) . As the main pathway of manganese clearance from the body is through the biliary system and the intestines, whole-body Mn-52 PET imaging following swallowing of manganese may be of interest for future studies of clearance of manganese from the body.
The major limitation of manganese as an MRI contrast agent in humans is its cellular toxicity and therefore the need to use as low a dose as possible. The FDA-approved doses of Mn 2+ contrast agents limit the use of MRI. Here, we showed that the higher sensitivity of PET over MRI enables the use of lower concentrations of manganese that may be applied for human studies. However, future use of Mn-PET in human studies may be limited by the dose and availability of the radiotracers. A recent study with Mn-51 reported dosimetry calculations of the effective dose equivalent (EDE) for standard adult male and female. For IV injection of the typical clinical dose of 370 MBq (10 mCi), Mn-51 was found to have an EDE of~15 mSv, which is comparable to the average dose used in FDG studies, of 14.1 mSv [44] . For local administration of Mn-52, more calculations are needed and dosimetry studies will be performed in the future. Despite the long half-life of Mn-52, it should be feasible for clinical use as it is similar to I-124 and I-131, with half-life of 4 and 8 days, respectively, which are used in humans specifically for thyroid applications, and as there is currently no other way to unambiguously trace direct connections in the human brain, making it interesting to pursue the use of Mn-52. Moreover, as opposed to the commonly used F-18 and C-11 radiotracers, manganese radionuclides are harder to produce, due to both the low availability of the target materials and the higher cyclotron energy and longer time needed to produce them. This may influence mostly studies with Mn-51, which need to be performed close to tracer production centers. Due to its longer half-life, Mn-52 can be shipped over long distance from the production center to imaging sites. However, further dosimetry calculations need to be performed to move these manganese radiotracers to clinical settings.
Another disadvantage of manganese radiotracers for PET compared to manganese as an MRI contrast agent is the lower resolution of PET. Together with partial volume effects and the small size of the rat, the relatively low resolution of PET limits our ability to study tracer distribution in rodents, especially for small organs such as the pancreas and specific areas in the brain. Thus, the larger NHP model was chosen to investigate additional aspects of Mn-PET. However, even in the NHPs, partial volume effect is common especially for small organs like the pancreas. Mn-51 PET's effective resolution is about 5.5 mm while the cross section of the NHP pancreas was about 10 mm as measured from the CT. The lower resolution of PET also prevents our ability to detect cytoarchitecture and fine structure in the brain and other organs in the body.
There is recent interest in PET/MRI systems that can be used for high resolution MRI image registration with PET. In particular, it can be beneficial for brain imaging in humans, where it may be possible for Mn-52 to be used to detect morphological and neuronal connection changes associated with neurodegenerative diseases over time. For example, Mn-52 PET can be used for brain imaging in multiple sclerosis patients, where the BBB in affected areas Saar G. et al.: Anatomy, Functionality, and Neuronal Connectivity with Mn-PET is disrupted; this allows Mn 2+ to enter the brain tissue faster and enhances manganese accumulation in lesions. Moreover, tracing from the lesion may quantitate the extent of tissue damage, as less manganese is expected to transport along damaged neuronal connections. In patients with traumatic brain injury, it may be useful both to assess the integrity of areas of BBB and to study the effects on brain connectivity after injury. Mn-PET may also potentially be used to map [ 52 Mn]Mn 2+ uptake in active brain areas after stimulation in a manner that can give complementary information for fMRI studies. Rodent studies with long stimulation times in the presence of Mn 2+ prior to imaging, showed high activity in stimulated areas such as motor cortex and auditory area, which were similar to BOLD fMRI results [48, 49] . , for PET imaging behave, in both rats and monkeys, in a manner similar to manganese ions in MEMRI studies that use much higher doses. This opens a wide variety of potential applications for their use in both preclinical and clinical studies to determine anatomy, function, and neuronal connectivity. This includes the detection of heart ischemia, liver metastases, tumors, and the assessment of renal and pancreatic function as well as imaging of neurodegeneration by tracking changes in neuronal connections.
Conclusions
